Top Price Market
  • Business
  • Politics
  • Investing
  • World
  • Business
  • Politics
  • Investing
  • World

Top Price Market

Investing

RAD 202 receives approval to start Phase 1 therapeutic trial

by December 20, 2024
December 20, 2024
RAD 202 receives approval to start Phase 1 therapeutic trial

Radiopharm Theranostics (RAD:AU) has announced RAD 202 receives approval to start Phase 1 therapeutic trial

Download the PDF here.

This post appeared first on investingnews.com
0
FacebookTwitterGoogle +Pinterest
previous post
House vote imminent on Trump-backed bill to avoid government shutdown
next post
Malls are using new restaurants to draw consumers as shopping centers reinvent themselves

You may also like

Ghana Expels Foreigners from Local Gold Market in...

Altech – Entitlement Offer & Share Placement to...

5 Artificial Intelligence ETFs

Prismo Metals Mobilizes for Palos Verdes Drilling

Financial Agreement signed releasing $2M grant

Element 25 Announces Share Purchase Plan

BP8 Sources Bird’s Nest Products from Chinese State-Owned...

Mining in Nunavik: An Emerging Hotbed for Critical...

Maverick Metals Secures US$19 Million to Fast Track...

Appia Rare Earths and Uranium Corp. to Present...

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest

    • Trump says 80% tariff on China ‘seems right’ ahead of weekend talks...

    • Crypto Market Recap: Bitcoin Breaks US$100,000 as ETF Inflows Rise, Coinbase Makes US$2.9 Billion Power Play

    • 7 Copper ETFs and ETNs

    • Trump’s tax hike proposal is ‘déjà vu’ of George H. W. Bush’s ‘read my lips’ moment, experts say

    • Pope Francis-era deal with Chinese Communist Party again under scrutiny as Pope Leo takes the reins

    Categories

    • Business (1,632)
    • Investing (4,784)
    • Politics (7,555)
    • Uncategorized (2)
    • World (6,138)
    • About us
    • Contacts
    • Privacy Policy
    • Terms & Conditions
    • Email Whitelisting

    Disclaimer: toppricemarket.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 toppricemarket.com | All Rights Reserved


    Back To Top